Vadadustat increases iron availability compared with darbepoetin in DD‐CKD–related anemia, as increased serum transferrin (measured as TIBC) is accompanied by decreased transferrin saturation, serum hepcidin, and serum ferritin. The gene discussed is HAMP; the disease is chronic kidney disease.